Septra

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

16 Active Studies for Septra

What is Septra

Trimethoprim

The Generic name of this drug

Treatment Summary

Sulfamethoxazole is an antibiotic that works by blocking the production of folic acid in bacteria, making it harder for them to grow and reproduce. This drug is usually taken in combination with trimethoprim, which also blocks a step in bacterial folic acid production. Together, these two drugs are very effective in treating bacterial infections of the urinary, respiratory, and gastrointestinal tracts.

Septra DS

is the brand name

image of different drug pills on a surface

Septra Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including Cholera and susceptible Enteritis infectious caused by Shigella sonnei .

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Septra Affects Patients

Sulfamethoxazole is an antibiotic that works by preventing bacteria from replicating. It is usually prescribed with trimethoprim, a drug that helps stop the growth of bacteria. Studies have found that taking both drugs together reduces the risk of developing a resistance than taking either one alone. Taking sulfamethoxazole may cause allergic reactions such as rashes or Stevens-Johnson syndrome, and should be stopped immediately if a rash appears. It can also contribute to folate deficiency, so it should be used with caution in those who are at a higher risk of developing a deficiency. People with glucose-6-phosph

How Septra works in the body

Sulfamethoxazole works to fight infection by stopping bacteria from producing folic acid. It does this by imitating the shape of a compound that the bacteria normally uses to make folic acid. By doing this, sulfamethoxazole blocks the bacteria's enzyme responsible for converting the compound into folic acid. This prevents the bacteria from making the folic acid it needs to make DNA and other important molecules, leading to a decrease in bacterial growth.

When to interrupt dosage

The suggested measure of Septra is contingent upon the identified disorder, for example, Urinary tract infection, Pneumocystis Jirovecii Pneumonia and Fluid replacement therapy. Dosage likewise relies upon the method of administration recorded in the table below.

Condition

Dosage

Administration

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Warnings

Septra Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Septra.

Common Septra Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Septra Toxicity & Overdose Risk

The lowest toxic dose of sulfamethoxazole in mice and rats is 2300mg/kg and 6200mg/kg, respectively. Symptoms of an overdose may include lack of appetite, stomach pain, nausea, vomiting, dizziness, headache, drowsiness, and loss of consciousness. Other signs may include fever, blood in the urine, and kidney stones. Long-term effects could include abnormal blood cells and yellowing of the skin. Treatment should be focused on managing symptoms and may include stomach pumping or inducing vomiting if necessary. Monitor the patient's lab work for evidence of blood or electrolyte imbalances.

image of a doctor in a lab doing drug, clinical research

Septra Novel Uses: Which Conditions Have a Clinical Trial Featuring Septra?

Presently, 8 active clinical trials are assessing Septra's potential to ameliorate Immunocompromised Patients, Fluid replacement therapy and susceptible Enteritis infections caused by Shigella sonnei.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

2 Actively Recruiting

Phase 3, Phase 4

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

12 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Septra Reviews: What are patients saying about Septra?

4.3

Patient Review

3/22/2010

Septra for Sinus Irritation and Congestion

I had a sinus infection and felt better after about a week of using this medication. I was prescribed it for 14 days and took it twice a day with no issues.

4

Patient Review

8/20/2012

Septra for Sepsis Caused by Bacteria

I didn't experience any adverse effects while taking this medication. I took one pill every day for two months, and it seemed to work well for me.

3.7

Patient Review

8/24/2010

Septra for Skin Infection

The beginning of this medication is tough, BUT it gets better. I had severe nausea the first day, black stool the next, but by the third day all subsided and I am feeling better. Although, do stay out of direct sunlight because your skin is way more suseptible to burning completely through your treatment.

3.7

Patient Review

2/25/2010

Septra for Continuous Bacterial Inflammation of the Prostate Gland

I've been struggling with a prostate infection for quite some time, so I was really desperate to try anything that might provide relief. Even though this medication made me feel nauseous, it was still worth it because it helped clear up the infection.

3.3

Patient Review

12/1/2009

Septra for Urinary Tract Infection caused by Klebsiella Bacteria

I got a UTI after taking this medication, but it did help to get rid of my fever. However, I broke out in a rash from head to toe.

3.3

Patient Review

1/31/2010

Septra for Sinus Irritation and Congestion

I found this antibiotic to be very slow-acting. I felt only slightly better after three days of use. I requested the cheapest option from my doctor due to my insurance, and I guess this is what you get when you're not well-off.

3

Patient Review

6/23/2010

Septra for Bacterial Urinary Tract Infection

I got headaches from this treatment, but I think they could have been mitigated if I had stayed hydrated.

2.3

Patient Review

7/3/2013

Septra for Skin Infection

I was prescribed this medication for acne. After the first two days of treatment, I began to get terrible headaches that caused me to discontinue the medication after five days of treatment. The headaches were debilitating and I never get side effects from medications.

2

Patient Review

7/20/2011

Septra for Sinus Irritation and Congestion

After taking this medication for a few days, I started experiencing extreme swelling in my mouth and throat. This was too much for me to handle so I had to stop.

1.7

Patient Review

6/20/2012

Septra for Urinary Tract Infection due to E. Coli Bacteria

I was prescribed the generic version of Septra, Sulfamethoxazole-TMP DS, and instructed to take one tablet twice a day. Within days, I started experiencing joint pain, muscle aches, headaches, and insomnia. On the fourth day of treatment, I developed a fever of 101 degrees Fahrenheit and was advised by my doctor to discontinue taking the medication because I was likely having a reaction to it. Thankfully, the fever disappeared the next day after stopping this medication. However, the side effects were awful and I would never take this drug again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about septra

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Septra used to treat?

"This medication is a combination of two antibiotics, sulfamethoxazole and trimethoprim. It can be used to treat various bacterial infections, such as those affecting the middle ear, respiratory system or intestines. It can also prevent and treat pneumonia caused by the pneumocystis virus."

Answered by AI

Is Septra and Bactrim the same?

"Sulfamethoxazole and trimethoprim are antibiotics that are used to treat bacterial infections. They are usually given together and sold under the brand names Bactrim or Septra. The combination of these antibiotics can treat a variety of infections, such as urinary tract infections (UTIs)."

Answered by AI

What type of bacteria does Septra treat?

"infections due to the bacteria Vibrio cholerae, Shigella, and Brucella; typhoid and paratyphoid fevers; infection of the intestine due to the Shigella bacteria; prevention of plague following exposure to plague; brain/spinal cord infection due to Listeria monocytogenes."

Answered by AI

Is Septra good for UTI?

"A three-day course of trimethoprim-sulfamethoxazole is recommended as empiric therapy for uncomplicated urinary tract infections in women, especially in areas where the resistance rate of Escherichia coli is less than 20 percent."

Answered by AI

Clinical Trials for Septra

Image of McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital in Montreal, Canada.

Systemic Corticosteroids for Pneumocystis Pneumonia

18+
All Sexes
Montreal, Canada

The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.

Phase 4
Waitlist Available

McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Septra clinical trials?

We made a collection of clinical trials featuring Septra, we think they might fit your search criteria.
Go to Trials
Image of University of Maryland, School of Medicine, Center for Vaccine Development and Global Health in Baltimore, United States.

Vaccine for E. coli Infections

18 - 49
All Sexes
Baltimore, MD

The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on an outpatient basis. All participants will receive 3 intramuscular (IM) doses of vaccine or placebo at 3-week intervals (days 1, 22 and 43). Following vaccination, participants will be followed as outpatients for safety using a memory aid from the time of each vaccination through 7 days post each vaccination. Approximately 28 days (plus or minus 1 day) after receipt of the 3rd dose of study agent, participants meeting challenge criteria will be admitted to an inpatient unit and be administered an oral dose of 1 x 10\^10 cfu (colony-forming unit) of ETEC strain B7A. Five days after challenge, participants will be treated with ciprofloxacin, except in cases of known allergy or intolerance. Participants will be discharged from the inpatient unit when they have completed their 3-day antibiotic course and are able to care for themselves. After discharge from the inpatient unit, participants will return for clinic visits and have a phone visit to provide any updates on medication, medical history and AE/SAEs. The primary objectives are: 1) Estimate CssBA+dmLT efficacy in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. 2) Evaluate the safety of intramuscular injection of CssBA+dmLT.

Phase 2
Waitlist Available

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health (+1 Sites)

Have you considered Septra clinical trials?

We made a collection of clinical trials featuring Septra, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Have you considered Septra clinical trials?

We made a collection of clinical trials featuring Septra, we think they might fit your search criteria.
Go to Trials